In partnership with
September 11, 2025
Built by a former cannabis regulator, Policy, Decoded is your high-signal daily briefing for operators, investors, and policymakers navigating the collision of law, regulation, and business.
Today’s edition is brought to you by Pacaso and The Daily Upside, whose support helps us deliver independent policy intelligence to your inbox.
The world feels heavier this week, and that weight is impossible to ignore. We’ll keep doing what we do best here: decoding the policy shifts shaping cannabis, hemp, and adjacent markets while giving you clear, grounded signals in a noisy environment. Texas regulators move from political theater to executive order, New York cracks down on lab testing failures, Maryland courts redefine hemp legality, and Congress pushes NIH into real-world cannabis research.
⚖️ Abbott’s executive order redraws Texas hemp
🧪 New York fines labs over contaminated cannabis
⚖️ Maryland declares delta-8 “never legal”
Stay steady. Read what matters.
Keep This Stock Ticker on Your Watchlist
They’re a private company, but Pacaso just reserved the Nasdaq ticker “$PCSO.”
No surprise the same firms that backed Uber, eBay, and Venmo already invested in Pacaso. What is unique is Pacaso is giving the same opportunity to everyday investors. And 10,000+ people have already joined them.
Created a former Zillow exec who sold his first venture for $120M, Pacaso brings co-ownership to the $1.3T vacation home industry.
They’ve generated $1B+ worth of luxury home transactions across 2,000+ owners. That’s good for more than $110M in gross profit since inception, including 41% YoY growth last year alone.
And you can join them today for just $2.90/share. But don’t wait too long. Invest in Pacaso before the opportunity ends September 18.
Paid advertisement for Pacaso’s Regulation A offering. Read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: Greg Abbott stepped in Wednesday to address hemp THC regulation after two special sessions left the issue unresolved, signing an executive order creating age restrictions and testing requirements for THC products. Despite ample time across both sessions, the Legislature couldn't bridge the gap between Abbott's regulatory preference and Dan Patrick's "poison in our public" demand for total prohibition. The order tells state agencies to ban sales to minors, beef up labeling standards, and jack up licensing fees to fund enforcement. Patrick's unwillingness to accept anything short of prohibition meant Abbott faced either calling a third special session or acting administratively. He chose administrative action one week after the second session expired without resolution.
💡 Why It Matters: Executive hemp regulation through administrative action carries significant legal risk, as California discovered with earlier gubernatorial intervention this year. Abbott's June veto of legislative prohibition cited federal law conflicts, and his administrative approach now tests whether states can regulate federally protected hemp without triggering preemption challenges. The Farm Bill permits hemp commerce including naturally derived THC, though synthetic cannabinoids like delta-8 and delta-10 remain more vulnerable to state restriction. Abbott's framework may face court challenges from hemp operators arguing federal preemption, particularly if enforcement targets naturally occurring compounds rather than synthetic derivatives. The move preserves Texas's expanding medical program while addressing youth access concerns that dominated legislative debates.
🧠 THC Group Take: Abbott's regulatory solution sidesteps Patrick's prohibition politics while creating potential federal preemption problems. The compliance framework acknowledges hemp's federal protection while asserting state authority over youth access and product safety - exactly the tension that could trigger court challenges. Legal vulnerability increases if enforcement targets naturally derived THC products protected under the Farm Bill rather than focusing on synthetic cannabinoids where state authority is clearer. Other governors considering similar administrative approaches should prepare for litigation testing the boundaries between federal hemp protections and state police powers. Court challenges appear inevitable given the tension between federal hemp commerce protections and state regulatory authority.
Fast-moving headlines, flagged for what matters.
New York’s Office of Cannabis Management announced it will pursue over $2 million in fines and a three-year ban against Lexachrom Labs, which surrendered its permit in June after clearing pesticide-contaminated cannabis for major brands including Stiiizy. The Long Island lab shut down during a state audit that triggered one of New York's biggest product recalls, involving 12 lots of cannabis flower that passed Lexachrom's testing but later failed when retested by another lab. OCM's enforcement represents the strongest action yet in a market approaching $2 billion in annual sales, joining a nationwide crackdown on testing labs accused of THC potency inflation and clearing contaminated products to please clients. The case highlights systemic issues with cannabis testing integrity, where labs compete for business by providing favorable results rather than accurate safety data. Lexachrom's closure after the fact raises questions about whether surrendering permits allows labs to escape meaningful punishment, potentially undermining deterrent effects for other operators engaging in questionable practices. (New York Times)
The Second Circuit ruled that New York's "Extra Priority" licensing advantage for applicants with New York marijuana convictions violated the dormant Commerce Clause, but the decision was narrowly tailored and leaves most equity frameworks intact. New York's system tripled queue position for applicants with New York-specific convictions, which the court found functioned as a residency proxy that categorically excluded otherwise qualified out-of-state applicants. The court explicitly found that Variscite could not challenge the November Pool processing order or the broader CAURD program structure, limiting the ruling's scope to the specific conviction requirement. The court noted that restorative justice goals could be met through neutral criteria like any cannabis conviction or economic need without favoring New Yorkers. This creates a manageable fix for states: broaden conviction eligibility beyond state-specific requirements while maintaining other equity criteria. The broader dormant Commerce Clause precedent matters more for future interstate commerce arguments than current licensing disruption. (Reuters)
The House Appropriations Committee approved language directing NIH to study cannabis products that reflect "the variety, quality and potency of commonly available cannabis strains" rather than continuing reliance on limited federal sources. The Labor-HHS spending bill report acknowledges that federal research has been "limited to marijuana from a single source" despite DEA approving additional manufacturers in recent years, creating a research gap between laboratory studies and actual consumer products from state dispensaries. The committee also ordered CDC, SAMHSA and NIDA to study cannabinoid hyperemesis syndrome prevalence among youth, citing concerns about high-THC vaping products with interim and final reports due within 180 days and one year respectively. The directive creates the surreal prospect of congressional staff researching whether studies should include strains like Wedding Cake or Purple Punch alongside the traditional government schwag. I’m hoping the Congressional Record will someday include references to Cat Piss and Alaskan Thunderfuck, too. While researchers still cannot access actual dispensary products due to federal constraints, watching Congress grapple with the reality that people aren't smoking the same leafy research material that's powered decades of studies offers a rare moment of policy meeting street-level truth. (Marijuana Moment)
The Maryland Appellate Court ruled Tuesday that delta-8 and delta-10 hemp products have "never been legal" in the state despite widespread availability since 2018 and existing age restriction laws preventing sales to those under 21. The court determined these psychoactive substances are illegal because they're created synthetically rather than occurring naturally in high quantities like THC in cannabis, overturning a previous circuit court injunction that allowed continued sales. Maryland Hemp Coalition attorney Nevin Young called the ruling "absurd," noting that age restriction laws inherently imply legal adult access, while the state can now enforce licensing requirements against unlicensed retailers selling these products. The decision creates regulatory chaos for businesses that have operated legally for years under previous interpretations, with the court essentially declaring that laws restricting youth access somehow prove adult prohibition. The ruling highlights the synthetic versus natural distinction that's becoming a key battleground in hemp regulation, potentially affecting similar products nationwide where courts grapple with Farm Bill interpretations. (Maryland Daily Record)
Multistate operators with Canadian affiliates could restructure north of the border, then seek US recognition under Chapter 15 bankruptcy provisions - bypassing federal restrictions that block traditional Chapter 11 proceedings for cannabis businesses. The strategy hinges on convincing US courts that cannabis restructuring isn't "manifestly contrary to public policy," with attorneys noting that DOJ hasn't forced state-legal operators to cease operations despite federal prohibition. Companies like StateHouse Holdings, MedMen and Herbl missed this opportunity, instead using costlier state receiverships combined with foreign proceedings to shed failing subsidiaries. Chapter 15 offers no trustee or bankruptcy estate, allowing companies to present favorable facts for reorganization while potentially protecting creditors through foreign court recognition. With 75% of cannabis operators reporting difficulty accessing traditional financing and facing severe tax burdens from Section 280E, the untested approach represents a potential lifeline for distressed multistate operators seeking alternatives to limited state-level remedies. (Bloomberg Law)
St. Louis County Council is considering a ban on intoxicating hemp derivatives like delta-8, with Councilwoman Lisa Clancy citing lack of age restrictions, colorful packaging targeting kids, and absence of testing requirements that regulated marijuana faces. Cannabis industry officials support the ban over safety concerns, while hemp retailers argue they sell responsibly and provide more accessible alternatives than expensive dispensary products. The debate highlights the regulatory patchwork where hemp products occupy legal gray areas in gas stations and convenience stores while regulated cannabis faces strict oversight and higher costs. Hemp sellers want consistent regulations rather than outright bans, with one operator noting hemp testing now exceeds standards for organic produce. The proposal failed at the state level this spring after bipartisan concerns about small business impacts, leaving local governments to address the regulatory vacuum between federal hemp legality and state cannabis frameworks. (St. Louis Post-Dispatch)
New Mexico's Cannabis Control Division is considering rules requiring all dispensary cannabis products to undergo lab testing, effectively eliminating hemp-derived CBD and CBN products that customers use for pain relief and sleep management. Dispensary owner Rachel McLaughlin warns the restrictions would affect "almost the whole store" including extracts, vape oils, sleep gummies, and terpene-infused CBD products that comprise significant inventory. The regulatory gap creates an absurd outcome where gas stations and hemp stores could continue selling cannabinoid products while licensed dispensaries face prohibition, potentially driving customers away from regulated businesses. Former legalization commission member Pat Davis calls the approach a "mishmash" with environmental and agricultural departments stepping in to regulate products that cannabis regulators want to ban. The proposal highlights regulatory confusion over hemp-derived products in legal cannabis markets, where agencies often prioritize theoretical compliance over practical consumer access and business viability. (KOAT New Mexico)
Switzerland's draft adult-use framework proposes a national monopoly for online cannabis sales, positioning itself as Europe's first commercial cannabis market while Germany's program faces setbacks. The single operator model prioritizes consumer protection over competition, drawing parallels to Ontario's Cannabis Store which generated C$246 million in net income last year with C$223 million returned as provincial dividends. Cannavigia, which already runs Switzerland's pilot project compliance infrastructure under an exclusive ten-year federal contract, emerges as a likely candidate if regulators tap private sector expertise rather than building from scratch. The approach reflects Switzerland's public health focus but raises innovation concerns, with industry observers noting the tension between state oversight and market dynamics. Ontario's experience suggests significant revenue potential for public health programs, though questions remain about whether Switzerland will build internally or leverage existing private infrastructure. (Business of Cannabis)
Rep. Greg Steube published an op-ed urging President Trump to reschedule cannabis from Schedule I to Schedule III, framing it as conservative policy that serves veterans, seniors, and patients rather than preserving "debunked myths" in Washington. The Florida Republican emphasizes that rescheduling isn't legalization but would enable serious research, proper safety standards, and allow doctors to prescribe medical marijuana without patient criminalization. Steube highlights VA care restrictions that deny services to veterans using state-legal medical marijuana, arguing rescheduling would give VA latitude to provide effective care with tested, safe products. His appeal comes as Trump faces pressure from multiple directions on cannabis policy, with Steube positioning rescheduling as an opportunity for the president to "disrupt" federal-state contradictions while advancing patient interests. The op-ed represents growing Republican comfort with medical cannabis arguments, particularly when framed around veteran care and federal overreach rather than broader legalization themes. (Washington Examiner)
Wall Street’s Morning Edge.
Investing isn’t about chasing headlines — it’s about clarity. In a world of hype and hot takes, The Daily Upside delivers real value: sharp, trustworthy insights on markets, business, and the economy, written by former bankers and seasoned financial journalists.
That’s why over 1 million investors — from Wall Street pros to Main Street portfolio managers — start their day with The Daily Upside.
Invest better. Read The Daily Upside.
The deeper pattern behind today’s moves — and why it matters next.
🧾 Context: Drugged driving keeps climbing while everyone argues about how to measure it. An 8-month-old died in Wisconsin when a cannabis-impaired driver ran a stop sign, highlighting what's becoming a bigger problem nationwide. About 12.6 million Americans drove after using illicit drugs in 2020, with nearly 12 million specifically using cannabis before getting behind the wheel. States are scrambling with wildly different approaches - some have zero-tolerance laws that nail you for any detectable substance, others set THC thresholds like Colorado's 5 nanograms trying to copy alcohol's playbook. Twenty-seven states now use roadside saliva tests, while others rely on cops eyeballing impairment or calling in drug recognition experts. NHTSA says cannabis doubles fatal crash risk but admits detection is messy, creating this impossible tension between keeping roads safe and actually proving someone was impaired.
🔎 What It Signals: Here's the problem nobody wants to talk about: we're trying to enforce cannabis impairment using alcohol rules, and it's completely backwards. Alcohol dissolves in water, gets processed predictably, and clears your system in hours. THC does the opposite - it loves fat cells, hides there for weeks, and trickles back into your blood long after you've sobered up. National Institute of Justice research found people showing "significantly decreased cognitive and psychomotor functioning" even with barely detectable THC levels, while others tested high but performed fine. Field sobriety tests designed for drunk drivers miss cannabis impairment entirely. So states like Colorado and Ohio are prosecuting based on blood levels that mean absolutely nothing for actual impairment. You could smoke a joint three days ago, be completely sober, and still get a DUI under per se laws. Meanwhile, someone actually impaired might test below the threshold and walk free.
🧠 THC Group Take: We're building an entire enforcement system on quicksand and pretending it's solid ground. The fat-soluble problem isn't getting fixed with better labs or fancier roadside tests - it's basic chemistry that makes THC behave nothing like alcohol. Current testing creates this perverse outcome where sober people get arrested while impaired drivers slip through because their blood levels don't match arbitrary thresholds. States keep doubling down on chemical detection because it feels scientific, but they're essentially prosecuting metabolites instead of impairment. The smarter play is behavioral testing combined with emerging tech like eye-tracking that actually measures what matters - whether someone can safely operate a vehicle right now. This requires admitting our current approach is largely theater and building something that acknowledges how cannabis actually works in the human body. Getting this wrong perpetuates the same enforcement disparities that defined prohibition, where flawed detection becomes another avenue for selective prosecution rather than genuine public safety improvement.
From the hearing room to the comment section — we’re watching it all.
🌿 The Netherlands' largest legal cannabis producer faces closure after 2,000 complaints about marijuana smell from its seven football pitch-sized greenhouses (roughly 11 acres). CanAdelaar, operating converted tomato facilities in Hellevoetsluis, must install air filters within a week or face $3.8 million in fines - highlighting how legalization's biggest challenge isn't always regulation but basic neighbor relations. (DutchNews)
📊 Pre-rolls generated $946 million across 69 million units in 2024, overtaking flower as Canada's top cannabis category for the first time. General Admission dominated with $110 million in sales through multipack strategies, suggesting mature legal markets naturally gravitate toward processed convenience products over traditional flower preparation. (Cannabis Business Times)